Plus   Neg

Celsion Corp. (CLSN) Soared After Data Presented At AACR

Celsion Corp. (CLSN) presented the final data from its Phase Ib clinical trial, combining GEN-1 with the standard of care, at the American Association of Cancer Research Special Conference.

Celsion climbed for the majority of Tuesday's session and finished up by 4.55 at $6.06 on the highest volume of the year. The stock surged to over a 7-month high.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Follow RTT